Jeffrey S Farrow sold $440k of TARS
See Remarks at Tarsus Pharmaceuticals, Inc.. 6,430 shares at an average of $68.36, traded Mar 17, 2026, filed Mar 19, 2026.
Score components
- +15RoleOfficer
- +17Trade size$440k at market
- +5Share of holdings soldSold 13% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001405253-26-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | SOpen-market sale Common Stock | -2,111 | $69.42 | $147k | 47,635 | Mar 19, 2026 |
| Mar 18, 2026 | SOpen-market sale Common Stock | -2,133 | $68.71 | $147k | 45,502 | Mar 19, 2026 |
| Mar 19, 2026 | SOpen-market sale Common Stock | -2,186 | $67.00 | $146k | 43,316 | Mar 19, 2026 |
Related signals
Other insiders at Tarsus Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Tarsus Pharmaceuticals, Inc. | William J Link Phd director | $980k 12,500 shares | -12% | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $906k 10,000 shares | -1% | |
| 55Moderate | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $1.2M 13,953 shares | -105% | |
| 31Weak | Tarsus Pharmaceuticals, Inc. | Seshadri Neervannan Chief Operating Officer | $388k 4,564 shares | -5% | |
| 42Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $801k 10,000 shares | -1% | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $898k 11,578 shares | -50% | |
| 27Weak | Tarsus Pharmaceuticals, Inc. | Seshadri Neervannan Chief Operating Officer | $200k 2,989 shares | -3% | |
| 85Strong | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $2.4M 34,603 shares | -51% | |
| 39Weak | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $78k 1,144 shares | -5% | |
| 58Moderate | Tarsus Pharmaceuticals, Inc. | Aziz Mottiwala Chief Commercial Officer | $893k 13,056 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.